Log in

OTCMKTS:QBIO - Q BioMed Stock Price, Forecast & News

$1.55
-0.04 (-2.52 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$1.42
Now: $1.55
$1.63
50-Day Range
$1.30
MA: $2.28
$3.45
52-Week Range
$0.34
Now: $1.55
$3.75
Volume64,781 shs
Average Volume132,492 shs
Market Capitalization$32.40 million
P/E RatioN/A
Dividend YieldN/A
Beta4.05
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; BM-001 for the treatment of rare pediatric nonverbal autism spectrum disorder; and Uttroside-B for liver cancer. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was founded in 2013 and is based in New York, New York.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:QBIO
Previous SymbolNASDAQ:QBIO
CUSIPN/A
Phone212-588-0022

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.26) per share

Profitability

Net Income$-10,280,000.00

Miscellaneous

Employees1
Market Cap$32.40 million
Next Earnings Date4/15/2020 (Estimated)
OptionableNot Optionable

Receive QBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for QBIO and its competitors with MarketBeat's FREE daily newsletter.


Q BioMed (OTCMKTS:QBIO) Frequently Asked Questions

How has Q BioMed's stock been impacted by COVID-19 (Coronavirus)?

Q BioMed's stock was trading at $1.5728 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QBIO shares have decreased by 1.4% and is now trading at $1.55. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Q BioMed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Q BioMed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Q BioMed.

When is Q BioMed's next earnings date?

Q BioMed is scheduled to release its next quarterly earnings announcement on Wednesday, April 15th 2020. View our earnings forecast for Q BioMed.

How were Q BioMed's earnings last quarter?

Q BioMed Inc (OTCMKTS:QBIO) posted its earnings results on Monday, July, 16th. The company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.10. View Q BioMed's earnings history.

Has Q BioMed been receiving favorable news coverage?

News articles about QBIO stock have trended very positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Q BioMed earned a coverage optimism score of 4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutQ BioMed.

Who are some of Q BioMed's key competitors?

What other stocks do shareholders of Q BioMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include Washington Trust Bancorp (WASH), NVIDIA (NVDA), Otonomy (OTIC), New Age Beverages (NBEV), Opko Health (OPK), Canopy Growth (CGC), Adobe (ADBE), Micron Technology (MU), Cyberark Software (CYBR) and Intel (INTC).

Who are Q BioMed's key executives?

Q BioMed's management team includes the following people:
  • Mr. Denis D. Corin, Chairman, CEO, Pres & CFO (Age 46)
  • Mr. William S. Rosenstadt, Gen. Counsel & Director (Age 51)
  • Mr. David Laskow-Pooley, VP of Product Devel. (Age 65)
  • Mr. Robert Derham, VP of Orphan Products
  • Mr. Ari Jatwes, Bus. Devel. Analyst

What is Q BioMed's stock symbol?

Q BioMed trades on the OTCMKTS under the ticker symbol "QBIO."

How do I buy shares of Q BioMed?

Shares of QBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Q BioMed's stock price today?

One share of QBIO stock can currently be purchased for approximately $1.55.

How big of a company is Q BioMed?

Q BioMed has a market capitalization of $32.40 million. The company earns $-10,280,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. Q BioMed employs 1 workers across the globe. View additional information about Q BioMed.

What is Q BioMed's official website?

The official website for Q BioMed is http://www.qbiomed.com/.

How can I contact Q BioMed?

Q BioMed's mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The company can be reached via phone at 212-588-0022.


MarketBeat Community Rating for Q BioMed (OTCMKTS QBIO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Q BioMed and other stocks. Vote "Outperform" if you believe QBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel